LAM Therapeutics Announces Progress of its Clinical Portfolio with FDA Clearance of New Trial in Leukemia and Advancement of Clinical Trial in Lymphoma GUILFORD, Conn., Nov. 30, 2017 (GLOBE NEWSWIRE) -- LAM Therapeutics (LAM), a 4Catalyzer company, advanced its clinical portfolio with the U.S. Food and Drug Administration (FDA) clearance of LAM’s...